Xtant reports Q4 EPS (2c) vs. (3c) last year

Reports Q4 revenue $15.3M vs. $14M last year. "Highlighted by strong fourth quarter revenue results and last week’s acquisition of the Coflex product line, we are executing on our key growth initiatives," said Sean Browne, President and CEO of Xtant Medical. "We continue to generate robust demand for our biologics products, which grew 14% for the quarter, and improve our operating efficiencies by increasing our production capacity that now has us well-positioned to sustain our momentum in 2023. Additionally, with the addition of the Coflex product line, we significantly enhanced our fixation offering at ASCs and outpatient facilities. We are excited to add proven treatment devices while expanding our commercial team and distributor network, all of which are core focus areas to our long-term growth strategy."